Serum paraoxonase-1 as biomarker for improved diagnosis of fatty liver in dairy cows

BMC Veterinary Research

Yoichiro Horii¹  Nariaki Nonaka¹  Eman Mohamed Fath²  Kazuyuki Honkawa²  Ayman Samir Farid¹ 

[1] Laboratory of Parasitic Diseases, Faculty of Agriculture, University of Miyazaki, Gakuen-Kibanadai, Nishi 1-1, Miyazaki 889-2192, Japan;Interdisciplinary Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Gakuen-Kibanadai, Nishi 1-1, Miyazaki 889-2192, Japan

关键词: Liver function;    Diagnosis;    Dairy cow;    Fatty liver;    Lactonase;    Arylesterase;    Paraoxonase;   

Others  :  1119565
DOI  :  10.1186/1746-6148-9-73

 received in 2012-09-20, accepted in 2013-04-05,  发布年份 2013

【 摘 要 】

Background

Fatty liver is a major metabolic disorder in dairy cows and is believed to result in major economic losses in dairy farming due to decreased health status, reproductive performance and fertility. Currently, the definitive means for diagnosing fatty liver is determining the fat content of hepatic tissue by liver biopsy, which is an invasive and costly procedure, making it poorly suited to dairy farms. Therefore, the key aim of this study was to investigate the measurement of serum paraoxonase-1 (PON1), an enzyme exclusively synthesized by the liver, as a sensitive noninvasive biomarker for diagnosis of fatty liver in dairy cows.

Results

A comparative cohort study using serum specimens from Holstein–Friesian dairy cows (46 healthy and 46 fatty liver cases) was conducted. Serum PON1 (paraoxonase, lactonase and arylesterase) activity and other biochemical and hematological parameters were measured. We found that serum PON1 activity was lower (P<0.001) in cows suffering from fatty liver. The area under the receiver operating characteristic curve (AUC-ROC) of PON1 activity for diagnosis of fatty liver was 0.973–0.989 [95% confidence interval (CI) 0.941, 1.000] which was higher than the AUC-ROC of aspartate aminotransferase (AST), lecithin-cholesterol acyltransferase (LCAT), alkaline phosphatase (ALP), non-esterified fatty acids (NEFA), beta-hydroxybutyrate (BHBA), total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL). We found that adding serum PON1 measurement to different batteries of serum diagnostic panels showed a combination of high sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odd ratio (DOR) and overall diagnostic accuracy in diagnosing fatty liver.

Conclusions

The present results indicate that addition of serum PON1 activity measurement to the biochemical profile could improve the diagnosis of fatty liver in dairy cows, which would have a considerable clinical impact and lead to greater profitability in the dairy industry.

【 授权许可】

   
2013 Farid et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jorritsma R, Jorritsma H, Schukken YH, Wentink GH: Relationships between fatty liver and fertility and some periparturient diseases in commercial Dutch dairy herds. Theriogenology 2000, 54(7):1065-1074.
• [2]Bobe G, Young JW, Beitz DC: Invited review: pathology, etiology, prevention, and treatment of fatty liver in dairy cows. J Dairy Sci 2004, 87(10):3105-3124.
• [3]Katoh N: Relevance of apolipoproteins in the development of fatty liver and fatty liver-related peripartum diseases in dairy cows. J Vet Med Sci 2002, 64(4):293-307.
• [4]Collins RA, Reid IM: A correlated biochemical and stereological study of periparturient fatty liver in the dairy cow. Res Vet Sci 1980, 28(3):373-376.
• [5]Grummer RR: Etiology of lipid-related metabolic disorders in periparturient dairy cows. J Dairy Sci 1993, 76(12):3882-3896.
• [6]Cebra CK, Garry FB, Getzy DM, Fettman MJ: Hepatic lipidosis in anorectic, lactating holstein cattle: a retrospective study of serum biochemical abnormalities. J Vet Intern Med 1997, 11(4):231-237.
• [7]Gerloff BJ, Herdt TH, Emery RS: Relationship of hepatic lipidosis to health and performance in dairy cattle. J Am Vet Med Assoc 1986, 188(8):845-850.
• [8]Kalaitzakis E, Panousis N, Roubies N, Giadinis N, Kaldrymidou E, Georgiadis M, Karatzias H: Clinicopathological evaluation of downer dairy cows with fatty liver. Can Vet J 2010, 51(6):615-622.
• [9]Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7(2):69-76.
• [10]Aviram M, Rosenblat M: Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005, 16(4):393-399.
• [11]Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003, 34(6):774-784.
• [12]Antončić-Svetina M, Turk R, Svetina A, Gereš D, Rekić B, Juretic D: Lipid status, paraoxonase-1 activity and metabolic parameters in serum of heifers and lactating cows related to oxidative stress. Res Vet Sci 2011, 90(2):298-300.
• [13]Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005, 46(6):1239-1247.
• [14]Turk R, Juretic D, Geres D, Svetina A, Turk N, Flegar-Mestric Z: Influence of oxidative stress and metabolic adaptation on PON1 activity and MDA level in transition dairy cows. Anim Reprod Sci 2008, 108(1–2):98-106.
• [15]Miyamoto T, Takahashi Y, Oohashi T, Sato K, Oikawa S: Bovine paraoxonase 1 activities in serum and distribution in lipoproteins. J Vet Med Sci 2005, 67(3):243-248.
• [16]Sonntag O: Dry chemistry: analysis with carrier-bound reagents. Amsterdam; London; New York: Elsevier; 1993.
• [17]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [18]Tietz NW, Finley PR, Pruden E, Amerson AB: Clinical guide to laboratory tests. 2nd edition. Philadelphia: Saunders; 1990.
• [19]Aviram M, Rosenblat M: Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 2008, 477:259-276.
• [20]Bruns DE, Huth EJ, Magid E, Young DS: Toward a checklist for reporting of studies of diagnostic accuracy of medical tests. Clin Chem 2000, 46(7):893-895.
• [21]Moses LE, Shapiro D, Littenberg B: Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993, 12(14):1293-1316.
• [22]Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM: The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56(11):1129-1135.
• [23]Graber M, Kohler S, Kaufmann T, Doherr MG, Bruckmaier RM, van Dorland HA: A field study on characteristics and diversity of gene expression in the liver of dairy cows during the transition period. J Dairy Sci 2010, 93(11):5200-5215.
• [24]Camps J, Marsillach J, Joven J: Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol 2009, 15(16):1929-1933.
• [25]Marsillach J, Aragones G, Beltran R, Caballeria J, Pedro-Botet J, Morcillo-Suarez C, Navarro A, Joven J, Camps J: The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 2009, 42(1–2):91-98.
• [26]Kumon Y, Suehiro T, Ikeda Y, Hashimoto K: Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci 2003, 73(22):2807-2815.
• [27]Feingold KR, Memon RA, Moser AH, Grunfeld C: Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139(2):307-315.
• [28]Ohtsuka H, Koiwa M, Hatsugaya A, Kudo K, Hoshi F, Itoh N, Yokota H, Okada H, Kawamura S: Relationship between serum TNF activity and insulin resistance in dairy cows affected with naturally occurring fatty liver. J Vet Med Sci 2001, 63(9):1021-1025.
• [29]James RW, Deakin SP: The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004, 37(12):1986-1994.
• [30]Nakagawa H, Oikawa S, Oohashi T, Katoh N: Decreased serum lecithin:cholesterol acyltransferase activity in spontaneous cases of fatty liver in cows. Vet Res Commun 1997, 21(1):1-8.
• [31]Sabesin SM, Hawkins HL, Kuiken L, Ragland JB: Abnormal plasma lipoproteins and lecithin-cholesterol acyltransferase deficiency in alcoholic liver disease. Gastroenterology 1977, 72(3):510-518.
• [32]Mudron P, Rehage J, Qualmann K, Sallmann HP, Scholz H: A study of lipid peroxidation and vitamin E in dairy cows with hepatic insufficiency. Zentralbl Veterinarmed A 1999, 46(4):219-224.
• [33]Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B: Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26(7–8):892-904.
• [34]Reid IM: Incidence and severity of fatty liver in dairy cows. Vet Rec 1980, 107(12):281-284.
• [35]Boyd JW: The mechanisms relating to increases in plasma enzymes and isoenzymes in diseases of animals. Vet Clin Pathol 1983, 12(2):9-24.
• [36]Kalaitzakis E, Roubies N, Panousis N, Pourliotis K, Kaldrymidou E, Karatzias H: Evaluation of ornithine carbamoyl transferase and other serum and liver-derived analytes in diagnosis of fatty liver and postsurgical outcome of left-displaced abomasum in dairy cows. J Am Vet Med Assoc 2006, 229(9):1463-1471.
• [37]Kaneko JJ, Harvey JW, Bruss M: Clinical biochemistry of domestic animals. 6th edition. Amsterdam; Boston: Academic Press/Elsevier; 2008.
• [38]Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y: Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000, 35(9):659-664.
• [39]Baird GD: Primary ketosis in the high-producing dairy cow: clinical and subclinical disorders, treatment, prevention, and outlook. J Dairy Sci 1982, 65(1):1-10.
• [40]González FD, Muiño R, Pereira V, Campos R, Benedito JL: Relationship among blood indicators of lipomobilization and hepatic function during early lactation in high-yielding dairy cows. J Vet Sci 2011, 12(3):251-255.
• [41]Mazur A, Ayrault-Jarrier M, Chilliard Y, Rayssiguier Y: Lipoprotein metabolism in fatty liver dairy cows. Diabete Metab 1992, 18(1 Pt 2):145-149.
• [42]Bionaz M, Trevisi E, Calamari L, Librandi F, Ferrari A, Bertoni G: Plasma paraoxonase, health, inflammatory conditions, and liver function in transition dairy cows. J Dairy Sci 2007, 90(4):1740-1750.
• [43]Rayssiguier Y, Mazur A, Gueux E, Reid IM, Roberts CJ: Plasma lipoproteins and fatty liver in dairy cows. Res Vet Sci 1988, 45(3):389-393.
• [44]Holtenius P: Plasma lipids in normal cows around partus and in cows with metabolic disorders with and without fatty liver. Acta Vet Scand 1989, 30(4):441-445.
• [45]Vazquez-Anon M, Bertics S, Luck M, Grummer RR, Pinheiro J: Peripartum liver triglyceride and plasma metabolites in dairy cows. J Dairy Sci 1994, 77(6):1521-1528.
• [46]Spady DK, Turley SD, Dietschy JM: Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver. J Lipid Res 1985, 26(4):465-472.
• [47]Uchida E, Katoh N, Takahashi K: The activity of lecithin:cholesterol acyltransferase in the serum of cows at parturition or with fatty liver. Vet Res Commun 1995, 19(5):343-351.
• [48]Basoglu A, Sevinc M, Birdane FM, Boydak M: Efficacy of sodium borate in the prevention of fatty liver in dairy cows. J Vet Intern Med 2002, 16(6):732-735.
• [49]Haudum A, Starke A, Beyerbach M, Wohlsein P, Rehage J: Ultrasonographic assessment of liver dimensions in dairy cows with different hepatic triacylglycerol content. J Anim Sci 2011, 89(5):1392-1400.
• [50]Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48(2):261-268.